PharmaCyte Biotech PMCB

PharmaCyte Biotech, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)

$3.98-12.83%close on Nov. 20, 2026 · volume 16K · Yahoo Finance

Price, last 64 sessions

$2.50$5.00$7.50Sept. 2026Oct. 2026Nov. 2026
Aug. 24, 2026 to Nov. 20, 2026 · high $8.73 · low $0.38 · SEC filing, placed when SEC released it

Our coverage

Insider buying and selling

No open-market insider buying or selling in the Form 4s filed since July 24, 2026.

Recent SEC filings

All 5 →
  • 8-KNov. 19, 2026, 5 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Financial statements and exhibits

    AI summary, unreviewedPharmaCyte Biotech Exchanges 851,304 Q/C Series G Warrants for 4,982,272 Unregistered Q/C Shares and Extends Q/C Series H Preferred Maturity

  • 8-KNov. 13, 2026, 4:28 p.m. ETView on SEC.govOur explainer

    Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits

    AI summary, unreviewedPharmaCyte Biotech (PMCB) to Effect 1-for-19 Reverse Stock Split Effective November 12, 2026 to Regain Nasdaq Minimum Bid Price Compliance

  • 8-KOct. 16, 2026, 5 p.m. ETView on SEC.gov

    Change in certifying accountant · Financial statements and exhibits

    AI summary, unreviewedPharmaCyte Biotech dismisses CBIZ CPAs as auditor, engages Grassi & Co. amid disclosed material weaknesses in internal controls

  • 10-QSept. 14, 2026, 4:05 p.m. ETView on SEC.gov
  • 10-KJuly 29, 2026, 4:58 p.m. ETView on SEC.gov